#Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals for Up to $25 Million,

Rallybio sells REV102 programme to Recursion for up to $25m

The deal, valued at up to $25m, includes an upfront equity payment of $7.5m and near-term milestones, extending Rallybio’s cash runway into mid-2027. The REV102 programme originated from The post Rallybio sells REV102 programme to Recursion for up to $25m appeared first on Pharmaceutical Business review.

#Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals for Up to $25 Million,

'Rallybio Sells Interest in Rare Disease Program to Recursion Pharmaceuticals for Up to $25 Million' NEW HAVEN, Conn. '' Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company focused on the development of transformative therapies for patients with rare and devastating diseases, announced today that it has executed a definitive agreement to sell its interest in the REV102 program to joint venture partner Recursion Pharmaceut…

Recursion takes full rights to rare genetic disorder drug; CStone out-licenses cancer drug in Europe

Plus, news about Basilea, BARDA, Inventiva and CTTQ: Recursion buys full rights to oral drug: The AI-driven biotech, which recently restructured, acquired the full rights to REV102, an ...